Introduction {#sec1-0300060516686872}
============

Despite the introduction of biologic therapies for the treatment of inflammatory diseases such as rheumatoid arthritis (RA) in the 1990s, there remain many unmet needs in the modern management of rheumatology at a global level. However, this global perspective cannot reflect the individual situations of patients in different countries and regions. Consequently, specific regional unmet needs are deserving of special examination, and here we will focus on RA patients in Qatar. The hot, humid climate, healthcare system and population demographics in this area of the world attribute unique considerations for practising rheumatologists in this region that may differ to those of specialists treating RA in the rest of the world. New therapies are currently being developed that aim to address some of these unmet needs, including novel oral therapies such as targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs).^[@bibr1-0300060516686872]^ It is widely expected that patients will prefer to receive an oral therapy over a subcutaneous **(SC)** or intravenous **(IV)** one,^[@bibr2-0300060516686872],[@bibr3-0300060516686872]^ but this may not be the case for all groups. Additionally, there are concerns about compliance and wasted drug with oral medication. To give regional guidance on the use of newly available therapies, we have conducted a patient preference and profile survey, the results of which are presented here alongside a review of the situation in Qatar and the wider Arabian Gulf region.

RA management in the Arabian Gulf {#sec2-0300060516686872}
---------------------------------

RA is a chronic inflammatory disease with an estimated prevalence of 0.5--1% in Northern Europe and North America.^[@bibr4-0300060516686872]^ However, there are few large epidemiological studies or good-quality registry data to suggest the disease's overall prevalence in the region of the Arabian Gulf.^[@bibr5-0300060516686872][@bibr6-0300060516686872]--[@bibr7-0300060516686872]^ Small population and hospital-based studies give wide variation, from 0.19% in rural Iran to 1.0% of the adult population in Lebanon and Iraq.^[@bibr8-0300060516686872][@bibr9-0300060516686872][@bibr10-0300060516686872][@bibr11-0300060516686872]--[@bibr12-0300060516686872]^ In Oman, the prevalence of RA in the population has been calculated at 8.4 cases per 1,000 adults (0.84%).^[@bibr13-0300060516686872]^

Disease severity also varies geographically, and it has traditionally been believed that most Arab patients with RA have a non-aggressive form of the disease.^[@bibr5-0300060516686872],[@bibr14-0300060516686872]^ These beliefs may lead to significant delays in diagnosis and treatment.^[@bibr15-0300060516686872]^ However, the disease severity is, in fact, comparable to that seen in other parts of the world,^[@bibr15-0300060516686872][@bibr16-0300060516686872]--[@bibr17-0300060516686872]^ with physicians reporting only 12% of patients in clinical practice having low disease activity in this region (LDA; defined as disease activity score (DAS) 28 \< 3.2).^[@bibr16-0300060516686872]^

It has long been accepted that there are cultural differences in how RA is managed in the Middle East.^[@bibr18-0300060516686872]^ Management practices vary widely -- often depending on the socioeconomic status of individual patients and complicated by local infrastructure or lack of it -- but there are signs that disease management strategy is evolving in the Middle East -- and the Gulf states in particular -- and many clinicians are now implementing up-to-date treatment guidelines and recommendations from international societies.^[@bibr5-0300060516686872],[@bibr15-0300060516686872]^ In Qatar, the majority of patients receive conventional synthetic (cs) DMARDs, and 64% of patients seen in the clinic achieve LDA or remission.^[@bibr19-0300060516686872]^ Yet despite this move towards modern practice, RA patients often experience a delay in diagnosis: a recent study in Dubai found erosions in 55% of patients, suggesting a delay in diagnosis and management.^[@bibr16-0300060516686872]^ A review examining the use of the European League Against Rheumatism (EULAR) recommendations in this region found that there were barriers to implementation, mainly for those individual recommendations that advocated aggressive management, early use of intensive therapy and frequent monitoring.^[@bibr15-0300060516686872]^ There still exists a significant regional unmet need in the management of RA.

Regional environmental considerations in the management of RA {#sec3-0300060516686872}
-------------------------------------------------------------

There are certain regional environmental considerations that impact the management of RA patients. The first of these relates to the climate, as summer temperatures in Qatar can surpass 49℃.^[@bibr20-0300060516686872]^ To prevent disruption of the "cold chain," biologic drugs are dispensed in a chilled bag from the pharmacy. Although air conditioning is common in cars and homes, it is not entirely ubiquitous for the poorest in society and there is a risk that medication may be spoiled.

Ramadan fasting -- a fundamental pillar of Islam -- may have an effect on patient compliance and disease activity.^[@bibr21-0300060516686872],[@bibr22-0300060516686872]^ Whilst patients with chronic diseases may not be required to fast during Ramadan, many still do, and this has an impact on adherence and disease activity.^[@bibr22-0300060516686872]^ Many patients prefer not to take oral or intravenous medications during fasting hours,^[@bibr21-0300060516686872]^ and as such, patients might only take their therapies after sunset and before sunrise.^[@bibr23-0300060516686872][@bibr24-0300060516686872]--[@bibr25-0300060516686872]^ This alteration in dosing schedule has a clear impact on compliance.^[@bibr21-0300060516686872]^ Some patients may not agree to medical procedures such as blood tests during Ramadan, which may have an impact on routine monitoring.^[@bibr21-0300060516686872]^ Anecdotally, RA patients often do better during Ramadan and feel well because they are fasting, but then flare afterwards.^[@bibr26-0300060516686872],[@bibr27-0300060516686872]^ There is some speculation that this may be because the foods traditionally eaten during the Ramadan month are better for RA patients than those consumed during the rest of the year, including an increase in protein consumption and a reduction in carbohydrate intake, and that fasting has a direct effect on laboratory parameters.^[@bibr26-0300060516686872][@bibr27-0300060516686872]--[@bibr28-0300060516686872]^ An important take-home point from the studies discussed here is that most patients did not receive any particular information about changing their treatment during Ramadan. More research is required in this area to further understand the effects of Ramadan on adherence and disease activity.

Given the unmet needs in this region, this study aimed to investigate the level of disease activity in the region and patients' preferences regarding the route of administration for their therapy.

Methods {#sec4-0300060516686872}
=======

The authors met at a face-to-face meeting in September 2014. On the basis of discussions, a cross-sectional patient survey was designed to collect data on the typical RA patient profile in the region ([Box 1](#table1-0300060516686872){ref-type="table"}). The survey was conducted among 294 consecutive patients across three clinics in Qatar. Ethics committee approval was waivered for this study as all RA patients at the three participating clinics within Qatar are registered in the regional RA registry, for which they provide signed consent for their data to be used for publication purposes. The predefined primary clinical end point was the preferred mode of application (oral, IV, SC) in comparison with the patient's currently employed mode of application for treatment and in relation to their disease activity. Summary statistics are reported as either a mean with the minimum and maximum range for continuous data (such as the age of the patient) or as a total for count data (such as the number of patients on each mode of application). Table 1.Demographics in 294 consecutive patients at three clinics in Qatar.Male (n = 71)Female (n = 223)Qatari nationalOtherQatari nationalOtherNumber, n (%)5 (7)66 (93)87 (39)136 (61)Age, mean years (range)51.2 (31--64)51.1 (24--75)50.8 (20--84)46.9 (16--73) Box 1.Survey questions.• Demographics: patient age, gender and nationality• Disease activity score (DAS)• Clinical disease activity score (CDAI)• Current route of administration \^ Oral alone \^ Injection ± oral \^ Intravenous ± oral• Preferred route of administration• Co-morbidities

Descriptive statistics were employed for the analysis of baseline demographics. Among the population analysed, the patients´ nationality was dichotomized into Qatari and non-Qatari patients.

The mode of application employed and preferred was analysed separately for IV, SC and oral administration. Whether patients treated with a certain mode of application were pre-treated with another mode of application was not analysed in this survey. For the analysis of co-morbid diseases the results focussed on cardiovascular conditions (including diabetes, hypertension, hyper/dyslipoproteinemia or other), none and not reported.

Results {#sec5-0300060516686872}
=======

In our patient survey, 76% of patients in the study clinics were female. The mean age for women was 48 years (range 16--84), and 51 years for men (range 24--75). Our patient survey also captured the split between Qatari nationals and non-Qatari nationals, with 93% of male patients and 61% of female patients in the study clinics being of a nationality other than Qatari ([Table 1](#table1-0300060516686872){ref-type="table"}).

Of the 294 patients in our survey across three clinics in Qatar, 69% expressed a preference for oral therapy, 23% for SC injection and 8% for intravenous administration ([Table 2](#table2-0300060516686872){ref-type="table"}). Highest patient preference was for oral therapy, with 85% of patients who received it expressing a preference to stay on oral therapy. In contrast, only 63% and 58% of intravenous and SC injection patients, respectively, indicated a preference to remain on their current method of administration ([Figure 1](#fig1-0300060516686872){ref-type="fig"}). The mean age of patients with recorded co-morbidities was 55 years (range 17--74), with 88 patients (30%) diagnosed with one or more cardiovascular diseases ([Table 3](#table3-0300060516686872){ref-type="table"}). Figure 1.Patient-preferred route of administration in comparison with current therapeutic route of administration -- current versus desired in 294 consecutive patients seen at three clinics in Qatar. Table 2.Survey results: Route of administration and patient preference in 294 consecutive patients seen at three clinics in Qatar.Male (n = 71)Female (n = 223)Total (N = 294)Qatari national (n = 5)Other (n = 66)Qatari national (n = 87)Other (n = 136)Current therapy Oral alone, n (%)3 (60.0)51 (77.0)44 (51.0)97 (71.0)195 (66.0) Subcutaneous injection ± oral, n (%)1 (20.0)5 (8.0)28 (32.0)30 (22.0)64 (22.0) Intravenous ± oral, n (%)1 (20.0)10 (15.0)15 (17.0)9 (7.0)35 (12.0)Preferred route of administration Oral alone, n (%)3 (60.0)49 (74.0)53 (61.0)99 (73.0)203 (69.0) Subcutaneous injection ± oral, n (%)1 (20.0)12 (18.0)23 (26.0)32 (24.0)69 (23.0) Intravenous ± oral, n (%)1 (20.0)5 (8.0)11 (13.0)5 (3.0)22 (8.0) Table 3.Survey results: Cardiovascular co-morbidities among patients at three clinics in Qatar[\*](#table-fn1-0300060516686872){ref-type="table-fn"}.Male (n = 71)Female (n = 223)Qatari national (n = 5)Other (n = 66)Qatari national (n = 87)Other (n = 136)One or more cardiovascular  co-morbidity, n (%)1 (50.0)16 (23.2)17 (19.6)44 (35.4) Diabetes, n (%)0 (0)6 (8.7)7 (8.0)18 (13.2) Hypertension, n (%)1 (50.0)10 (14.5)8 (9.2)27 (19.9) Hyperlipidemia, dyslipidaemia  or hypercholesterolemia, n (%)0 (50.0)4 (5.8)8 (9.2)8 (5.9) Other, n (%)0 (0)2 (2.9)10 (11.5)8 (5.9)None, n (%)0 (0)17 (24.6)38 (43.7)31 (22.8)Not reported, n (%)1 (50.0)36 (52.2)32 (36.8)61 (44.9)[^1]

The level of disease activity in RA patients is most commonly measured via DAS and/or clinical disease activity index (CDAI). The level of disease activity can be interpreted as *low* (2.6 \< DAS28 ≤ 3.2) (2.8 \< CDAI ≤ 10), moderate (3.2 \< DAS ≤ 5.1) (10 \< CDAI ≤ 22), or *high* (DAS \> 5.1) (CDAI \> 22) with a DAS ≤ 2.6 or CDAI ≤ 2.8 corresponding to remission.^[@bibr29-0300060516686872]^ In our survey, whilst DAS was recorded in only 256 patients, CDAI was recorded in all 294 (mean overall score 9.07; range 0--55). There was agreement between DAS and CDAI in 79% of the cases. In the remaining patients, two-thirds showed a DAS higher than the CDAI and one-third had a CDAI higher than DAS ([Table 4](#table4-0300060516686872){ref-type="table"}). Our results show that, among the patients in our survey, over half had not yet achieved a CDAI LDA score (2.8 CDAI ≤ 10) with their current treatment ([Table 4](#table4-0300060516686872){ref-type="table"}). Table 4.Disease activity in 294 consecutive patients at three clinics in Qatar[\*](#table-fn3-0300060516686872){ref-type="table-fn"}.Male (n = 71)Female (n = 223)Qatari national (n = 5)Other (n = 66)Qatari national (n = 87)Other (n = 136)Total (N = 294)CDAI, mean (range)1.90 (0--5)9.34 (0--55)9.35 (0--52)9.03 (0--43.9)9.07 (0--55)CDAI LDA, n (%)1 (0.3)27 (9.2)36 (12.2)67 (22.8)131 (44.5)CDAI remission, n (%)4 (1.4)18 (6.1)21 (7.1)26 (8.8)69 (23.4)DAS[\*](#table-fn3-0300060516686872){ref-type="table-fn"}, mean (range)2.07 (1.3--3.1)3.28 (0.63--6.92)3.52 (1.25--7.21)3.57 (0.56--6.84)3.47 (0.56--7.21)DAS LDA, n^[†](#table-fn4-0300060516686872){ref-type="table-fn"}^19121739DAS remission, n^[†](#table-fn4-0300060516686872){ref-type="table-fn"}^419223277[^2][^3][^4]

Among patients surveyed for whom the level of disease activity was recorded, the majority (70%) with a recorded DAS of LDA or remission preferred the option of an oral therapy. The majority of patients with a recorded DAS of high disease activity also preferred the option of an oral therapy (77%). These high percentages for a preferred oral therapy were also reflected across the CDAI scores collected in our survey. Of those patients with a CDAI score of LDA or remission, 53% preferred the option of an oral therapy, and of those with a CDAI score of high disease activity, 74% preferred the option of an oral therapy.

Discussion {#sec6-0300060516686872}
==========

Social and access considerations {#sec7-0300060516686872}
--------------------------------

Several key social considerations have a bearing on access to therapy for RA patients in the Arabian Gulf. A patient's preferred route of administration for their therapy is often cited as a barrier to receiving therapy. It is assumed that patients prefer oral therapy, and several studies across a variety of chronic diseases have indeed found this pattern.^[@bibr30-0300060516686872][@bibr31-0300060516686872][@bibr32-0300060516686872][@bibr33-0300060516686872]--[@bibr34-0300060516686872]^ Research suggests that 44% of RA patients are not confident in administering their own injections.^[@bibr2-0300060516686872]^ Patients in these countries are also often undertreated^[@bibr5-0300060516686872],[@bibr16-0300060516686872]^ and there is wide variation in treatment, with 5% of patients in the United Arab Emirates (UAE) and 29% in Qatar receiving a biologic, compared with over 40% of eligible patients in the USA.^[@bibr19-0300060516686872]^ In part, this can be attributed to the high socioeconomic burden of other more prevalent diseases in the Middle East and Arabian Gulf countries, such as diabetes.^[@bibr15-0300060516686872]^ Public awareness regarding RA is also generally low in the region, but data from the UAE show that the introduction of patient support groups and disease awareness campaigns are beginning to show an effect.^[@bibr35-0300060516686872]^

Of particular note are the population dynamics, which are unique in the region and have a direct impact on healthcare provision and health economics. In particular, Qatar has an unusually high rate of temporary expatriates: Qatari nationals make up only about 6% of the overall adult population, with the majority of the country's residents being migrant workers from Asia, Africa and Europe.^[@bibr36-0300060516686872]^ In a recent cross-sectional study of 100 consecutive rheumatology patients at Hamad General Hospital in Doha, less than a quarter of patients were Qatari nationals; the majority (59%) were immigrant workers from Asia. Most of the Qatari patients were female (91%) compared with only 53% of the Asian patients, which reflects the high proportion of male immigrant workers.^[@bibr19-0300060516686872]^ In our survey, we found that less than a third of patients from the three clinics were Qatari nationals and that these were almost exclusively women (95%), compared with only 67% of non-national female patients.

This population skew has a direct bearing on clinical practice, since Qatari nationals receive free healthcare but non-Qatari immigrants do not -- although those with a residency visa have free access to primary and emergency healthcare services and pay only 20% of the costs of speciality healthcare services and drugs.^[@bibr19-0300060516686872]^ The Doha study found that 65% of Qatari national patients received biologic therapies, compared with 15% of eligible Asian immigrants.^[@bibr19-0300060516686872]^ Whilst some workers have medical insurance, the majority of immigrant labourers do not, and they cannot always pay for treatment. It is quite typical for these patients to visit their rheumatologist only when they can afford it, and this means that they are often untreated and flaring. Additionally, workers may return to their home country for extended periods between contracts and, as such, they are lost to follow-up in the clinic. This high proportion of expatriates and lack of appropriate medical insurance were cited as key reasons why physicians in countries in the region have been unable to implement the EULAR recommendations in clinical practice.^[@bibr15-0300060516686872]^ The results of our survey align with the region, representing varying and heterogeneous patient populations and the challenge this presents for clinicians looking to adopt guidelines or recommendations.^[@bibr5-0300060516686872]^ By the end of 2015, under new compulsory health insurance legislation in Qatar, it will be a requirement for companies to insure all non-Qatari workers,^[@bibr37-0300060516686872]^ although the policies may not cover modern biologic therapies. For these workers, in particular, affordable oral therapies that can easily be transported and self-administered may prevent patients from taking breaks from therapy that may cause serious long-term damage to their joints.

The literature reports typical patient profiles in the Arab region as being predominantly female, with a mean age of around 40 years at assessment.^[@bibr12-0300060516686872],[@bibr19-0300060516686872],[@bibr35-0300060516686872],[@bibr38-0300060516686872][@bibr39-0300060516686872]--[@bibr40-0300060516686872]^ Patient age is an important factor that may also impact treatment decisions^[@bibr41-0300060516686872]^ -- not least because older patients tend to have more co-morbidities, such as diabetes and heart failure. In our survey, the mean age of patients with recorded co-morbidities was 55 years (range 17--74), with 88 patients (30%) diagnosed with cardiovascular diseases ([Table 3](#table3-0300060516686872){ref-type="table"}). These numbers are of particular importance -- in 2012, four Gulf Cooperation Council countries (Saudi Arabia, Kuwait, Qatar and Bahrain) were among the top ten countries for highest diabetes prevalence rates in the world, with 20.52%, 17.87%, 16.28% and 17.53% of patients affected, respectively.^[@bibr42-0300060516686872]^

There are several limitations to this study. First, only the mode of application of treatment was assessed through the survey; therapy type was not specified, with no direct comparisons between different therapies being drawn. Second, further clinical subgroups, including length of time on treatment, socioeconomic status and patient-reported outcomes, were not defined. Future research into these areas could further build upon the current landscape and patient profiles within the region.

The future of RA therapy {#sec8-0300060516686872}
------------------------

Whilst there are clear unmet needs remaining for RA patients in the Arabian Gulf region, there are new oral tsDMARD therapies both available and in development that may offer some benefit. As well as the obvious benefits for needle-phobic patients or those who are unwilling or unable to inject themselves, these therapies are expected to be cheaper than biologics and will not be subject to the same requirements for cold storage, which may make them more suitable for populations exposed to hot summers and periods of travel. Additionally, new oral tsDMARD therapies can be taken with or without food,^[@bibr43-0300060516686872]^ and are therefore not expected to have any food interactions that would complicate the dosing schedule during Ramadan. However, these new therapies will require a shift in clinical practice to be accommodated.

Our group's clinical advice for rheumatologists considering using new oral tsDMARD therapies in their patients is based on the European and US experience to date.^[@bibr44-0300060516686872][@bibr45-0300060516686872]--[@bibr46-0300060516686872]^ Patients with autoimmune diseases, such as RA, are at increased risk for infections,^[@bibr45-0300060516686872]^ but biologic and new oral tsDMARD therapies may make patients more susceptible to opportunistic infections.^[@bibr47-0300060516686872]^ At the forefront are recommendations for vaccination against herpes zoster (HZ), as high numbers of cases of HZ were observed in clinical trials of some new therapies.^[@bibr48-0300060516686872]^ The routine measurement of varicella titres in patients is recommended: patients found to have a protective range can safely start therapy, but those with low titres should receive varicella or zostervax vaccine 2--3 weeks before starting therapy. Individual vaccination status should always be checked by the rheumatologist and updated prior to the initiation of any immunomodulatory therapy.^[@bibr44-0300060516686872],[@bibr46-0300060516686872]^ Tuberculosis (TB) has a prevalence of 3--43/100,000 persons in the region.^[@bibr49-0300060516686872]^ The advice and recommendations for the prevention and management of TB in patients receiving new oral tsDMARD therapies are the same as those for biologics, with new patients receiving a skin test prior to initiation of therapy and every year thereafter.

It is this group's recommendation that all physicians should endeavour to record the CDAI for every patient to gain a full picture of the disease burden and pattern. In order for disease remission to be an implementable target, both in clinical studies and in practice, it needs to be easy to calculate at the bedside. Aletaha et al.^[@bibr50-0300060516686872]^ demonstrated that simpler composite indices using an arithmetic sum of the same components (SDAI and CDAI) correlate well with DAS. Recently, in Qatar, there has been a change in clinical practice in the use of disease measurements. It is becoming increasingly common to record the CDAI at every patient visit, although DAS is still used for registry data collection.

Despite advances in treatment and management strategies, discord and misconception around the prevalence, severity and burden of RA persist in the Arabian Gulf region and represent a key barrier to early and appropriate treatment.^[@bibr15-0300060516686872]^ Overall, a preference for oral therapies over injection or infusion was observed in this study, and the greatest patient preference was for oral therapies. Whilst this survey did not capture the reasons for the patients' preferred route of administration, it is suspected that oral therapy is considered more convenient in this highly mobile, working population. On this basis, we recommend that the incorporation of new oral tsDMARD therapies into clinical practice will help to fulfil the current unmet treatment needs and alleviate the burden on patients and healthcare resources.
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[^1]: Data received from 56% of patients surveyed.

[^2]: CDAI: clinical disease activity index; DAS: disease activity score; LDA: low disease activity.

[^3]: DAS was calculated on only those patients with relevant data available (n = 256).

[^4]: ^†^The percentage of patients with an LDA or remission DAS score was not calculated as DAS scores were not collected for all patients.
